Bronchial Spasm Market Trends

Growth Drivers

Growing Demand for Inhalers to Boost the Market Growth - For instance, more than 5000 individuals are recommended to use reliever inhalers annually worldwide.
Increasing Prevalence of Fungal Infection - For instance, more than 100 million cases of fungal infections are diagnosed worldwide annually and nearly 1.5 million deaths are caused by these fungal infections.
Fungal infection in the lungs most commonly results in asthma since fungi are responsible to colonize the tracheobronchial tree with adequate release of antigens. These antigens can either trigger or worsen asthma. Aspergillus is the most common fungus to cause lung infections. Hence, such a prevalence of fungal infection is estimated to propel the market growth over the forecast period.
Rising Cases of COPD Across the Globe- As of 2019, approximately 3 million people died due to chronic obstructive pulmonary disease (COPD) making it 3^rd leading disease to cause death globally.
Remarkable Increment in the Healthcare Expenditure- World Bank released a set of data stating the health expenditure to hit USD 1,121 per capita in 2019.

Challenges

Higher Cost Associated with Treatment
Shortage of Medication and Skilled Medical Professionals
Lack of Awareness in Rural Areas of the Related Diseases

Bronchial Spasm Market: Key Insights

Base Year	2022
Forecast Year	2023-2033
CAGR	~5%

Frequently Asked Questions (FAQ)

Increasing prevalence of fungal infection and rising cases of COPD across the globe are estimated to majorly boost the market growth.

The market is anticipated to attain a CAGR of 5% over the forecast period, i.e., 2023-2033.

Shortage of medication and skilled medical professionals is estimated to challenge the market growth.

The market in North America region is projected to hold the largest market share by the end of 2033 and provide more business opportunities in the future.

The major players in the market are Sunovion Pharmaceuticals Inc., Merck & Co., Inc., Viatris Inc., Pfizer Inc., The Bristol-Myers Squibb Company, Sanofi S.A, Teva Pharmaceutical Industries Ltd. and others.

The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue-generating capacity as well as the new products being launched into the market by the company.

The market is segmented by treatment type, diagnosis, cause, end-user, and region.

The short-acting bronchodilators segment is anticipated to garner the largest market size by the end of 2033 and display significant growth opportunities.

Bronchial Spasm Market Trends